Featured Research

from universities, journals, and other organizations

High-dose vitamin D may not be better than low-dose vitamin D in treating multiple sclerosis

Date:
October 24, 2011
Source:
American Academy of Neurology
Summary:
Low vitamin D levels are associated with an increased risk of developing multiple sclerosis (MS), but the first randomized, controlled trial using high-dose vitamin D in MS did not find any added benefit over and above ongoing low-dose vitamin D supplementation, according to a new study.

Low vitamin D levels are associated with an increased risk of developing multiple sclerosis (MS), but the first randomized, controlled trial using high-dose vitamin D in MS did not find any added benefit over and above ongoing low-dose vitamin D supplementation, according to a study published in the Oct. 25, 2011, issue of Neurology, the medical journal of the American Academy of Neurology.

"We did not find added benefit from high-dose vitamin D over and above ongoing low-dose vitamin D supplementation, but these results need to be confirmed with larger studies," said Mark S. Stein, MBBS, PhD, FRACP, of The Royal Melbourne Hospital and The Walter and Eliza Hall Institute of Medical Research in Parkville, Australia.

The six-month study involved 23 people with the relapsing-remitting form of MS. All of the participants received low-dose vitamin D (1,000 international units daily) to prevent any vitamin D deficiency. Half of the participants also received high-dose vitamin D2 to elevate their blood vitamin D to high levels (with a target serum 25-hydroxyvitamin D level of 130-175nM). The other half received a placebo high-dose.

MRI scans of the participants' brains were performed at the start of the study and again after four, five and six months. There was no significant difference between the two groups in the number of new abnormalities that had formed in the brain after six months and no significant difference in the change in the total volume of brain abnormalities.

Four of the 11 people taking the high-dose vitamin D, or 37 percent, had a relapse where their MS symptoms worsened during the study, while none of the 12 people taking only low-dose vitamin D had any relapses.

Stein noted that the study involved people who had MS for an average of six years. "It's possible that studies of high-dose vitamin D at an earlier stage of MS may lead to different results," he said.

This study was supported by The Myer Foundation in Melbourne, Australia.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. S. Stein, Y. Liu, O. M. Gray, J. E. Baker, S. C. Kolbe, M. R. Ditchfield, G. F. Egan, P. J. Mitchell, L. C. Harrison, H. Butzkueven, T. J. Kilpatrick. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology, 2011; 77 (17): 1611-1618 DOI: 10.1212/WNL.0b013e3182343274

Cite This Page:

American Academy of Neurology. "High-dose vitamin D may not be better than low-dose vitamin D in treating multiple sclerosis." ScienceDaily. ScienceDaily, 24 October 2011. <www.sciencedaily.com/releases/2011/10/111024164701.htm>.
American Academy of Neurology. (2011, October 24). High-dose vitamin D may not be better than low-dose vitamin D in treating multiple sclerosis. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2011/10/111024164701.htm
American Academy of Neurology. "High-dose vitamin D may not be better than low-dose vitamin D in treating multiple sclerosis." ScienceDaily. www.sciencedaily.com/releases/2011/10/111024164701.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins